Xiamen Amoytop Biotech Co Ltd - Asset Resilience Ratio
Xiamen Amoytop Biotech Co Ltd (688278) has an Asset Resilience Ratio of 4.69% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See working capital to net assets of Xiamen Amoytop Biotech Co Ltd to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2020–2024)
This chart shows how Xiamen Amoytop Biotech Co Ltd's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see Xiamen Amoytop Biotech Co Ltd assets under control.
Liquid Assets Composition Over Time
This chart breaks down Xiamen Amoytop Biotech Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read how much debt does Xiamen Amoytop Biotech Co Ltd carry for a breakdown of total debt and financial obligations.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥150.59 Million | 4.69% |
| Total Liquid Assets | CN¥150.59 Million | 4.69% |
Asset Resilience Insights
- Limited Liquidity: Xiamen Amoytop Biotech Co Ltd maintains only 4.69% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Xiamen Amoytop Biotech Co Ltd Industry Peers by Asset Resilience Ratio
Compare Xiamen Amoytop Biotech Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Abivax SA
PA:ABVX |
Biotechnology | 2.58% |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252 |
Biotechnology | 2.03% |
|
Neuren Pharmaceuticals Ltd
AU:NEU |
Biotechnology | 90.43% |
|
Lifecome Biochemistry Co Ltd
SHE:002868 |
Biotechnology | 4.69% |
|
Pulike Biological Engineering
SHG:603566 |
Biotechnology | 17.82% |
|
Rocket Pharmaceuticals Inc
NASDAQ:RCKT |
Biotechnology | 14.00% |
|
NEWRON PHARMACEUT. EO-20
XETRA:NP5 |
Biotechnology | 41.67% |
|
Upstream Bio, Inc.
NASDAQ:UPB |
Biotechnology | 64.70% |
Annual Asset Resilience Ratio for Xiamen Amoytop Biotech Co Ltd (2020–2024)
The table below shows the annual Asset Resilience Ratio data for Xiamen Amoytop Biotech Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 9.51% | CN¥289.96 Million ≈ $42.43 Million |
CN¥3.05 Billion ≈ $446.37 Million |
-1.41pp |
| 2023-12-31 | 10.91% | CN¥257.08 Million ≈ $37.62 Million |
CN¥2.36 Billion ≈ $344.77 Million |
-4.40pp |
| 2022-12-31 | 15.31% | CN¥270.78 Million ≈ $39.62 Million |
CN¥1.77 Billion ≈ $258.80 Million |
+1.52pp |
| 2021-12-31 | 13.79% | CN¥196.38 Million ≈ $28.74 Million |
CN¥1.42 Billion ≈ $208.40 Million |
-8.70pp |
| 2020-12-31 | 22.49% | CN¥268.22 Million ≈ $39.25 Million |
CN¥1.19 Billion ≈ $174.53 Million |
-- |
About Xiamen Amoytop Biotech Co Ltd
Xiamen Amoytop Biotech Co., Ltd. engages in research, development, production, and sale of recombinant protein drugs in China. The company provides solutions for diseases, such as viral hepatitis, malignant tumors, and immunotherapy. Xiamen Amoytop Biotech Co., Ltd. was founded in 1996 and is based in Xiamen, China.